References

Epidemiological features of cardiovascular disease in Asia

10.1016/j.jacasi.2021.04.007 · 2021 · External reference

Addressing the global burden of CVD through "ACCelerated" action

10.1016/j.jacc.2023.05.015 · 2023 · External reference

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes

10.1093/eurheartj/ehz425 · 2020 · External reference

2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS)

10.1093/eurheartj/ehae177 · 2024 · External reference

Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review

10.1016/j.jacc.2018.09.042 · 2018 · External reference

How to diagnose and manage angina without obstructive coronary artery disease: Lessons from the British Heart Foundation CorMicA Trial

10.15420/icr.2019.04.r1 · 2019 · External reference

Ischaemia with no obstructive coronary arteries: A review with focus on the Asian population

10.4103/singaporemedj.smj-2023-116 · 2024 · External reference

Natural history of patients with ischemia and no obstructive coronary artery disease: The CIAO-ISCHEMIA study

10.1161/circulationaha.120.046791 · 2021 · External reference

Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: Prospective cohort study

2017 · External reference

2013 ACC/AHA Guideline on the assessment of cardiovascular risk

10.1016/j.jacc.2013.11.005 · 2014 · External reference

Radiomic analysis of myocardial native T1 imaging discriminates between hypertensive heart disease and hypertrophic cardiomyopathy

10.1016/j.jcmg.2018.11.024 · 2019 · External reference

Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland

10.1016/s0140-6736(24)02679-5 · 2025 · External reference

Frontiers in subclinical atherosclerosis and the latest in early life preventive cardiology

10.4103/singaporemedj.smj-2024-169 · 2025 · External reference

2020 Asian Pacific Society of cardiology consensus recommendations on antithrombotic management for high-risk chronic coronary syndrome

10.15420/ecr.2020.45 · 2021 · External reference

Exercise-based cardiac rehabilitation for coronary heart disease

10.1016/j.jacc.2015.10.044 · 2016 · External reference

Diagnostic and prognostic value of stress cardiovascular magnetic resonance imaging in patients with known or suspected coronary artery disease: A systematic review and meta-analysis

10.1001/jamacardio.2023.1290 · 2023 · External reference

Stress cardiac magnetic resonance myocardial perfusion imaging: JACC review topic of the week

10.1016/j.jacc.2021.08.022 · 2021 · External reference

Myocardial perfusion echocardiography and coronary microvascular dysfunction

10.4330/wjc.v7.i12.861 · 2015 · External reference

Myocardial contrast echocardiography

10.1161/circulationaha.107.747303 · 2008 · External reference

Use of cardiac imaging in chronic coronary syndromes: The EURECA imaging registry

10.1093/eurheartj/ehac640 · 2023 · External reference

Optimal medical therapy with or without PCI for stable coronary disease

10.1056/nejmoa070829 · 2007 · External reference

Initial invasive or conservative strategy for stable coronary disease

10.1056/nejmoa1915922 · 2020 · External reference

ESC e-cardiology working group position paper: Overcoming challenges in digital health implementation in cardiovascular medicine

10.1177/2047487319832394 · 2019 · External reference

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes

10.1056/nejmoa1504720 · 2015 · External reference

Liraglutide and cardiovascular outcomes in type 2 diabetes

10.1056/nejmoa1603827 · 2016 · External reference

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

10.1056/nejm200001203420301 · 2000 · External reference

Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis

10.1001/jama.2016.13985 · 2016 · External reference

Atherosclerotic cardiovascular disease landscape in Singapore

10.3389/fcvm.2024.1342698 · 2024 · External reference

Ministry of health clinical practice guidelines: Lipids

10.11622/smedj.2017018 · 2017 · External reference

Asian pacific society of cardiology consensus recommendations on dyslipidaemia

10.15420/ecr.2021.36 · 2021 · External reference

Unresolved reference

1994 · External reference

Ezetimibe added to statin therapy after acute coronary syndromes

10.1056/nejmoa1410489 · 2015 · External reference

Evolocumab and clinical outcomes in patients with cardiovascular disease

10.1056/nejmoa1615664 · 2017 · External reference

Alirocumab and cardiovascular outcomes after acute coronary syndrome

10.1056/nejmoa1801174 · 2018 · External reference

Asia-Pacific Real-World evolocumab use, LDL-C reduction, physician goals, and patient perceptions: HALES observational study

10.1007/s40119-024-00384-3 · 2024 · External reference

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol

10.1016/j.jacc.2018.11.003 · 2019 · External reference

PD11 cost-effectiveness analysis of inclisiran for treating primary hypercholesterolaemia and mixed dyslipidaemia in Singapore

10.1017/s0266462324002794 · 2024 · External reference

Efficacy and safety of inclisiran in Asian patients: Results from ORION-18

10.1016/j.jacasi.2023.09.006 · 2024 · External reference

Cholesterol goal achievement and lipid-lowering therapy in patients with stable or acute coronary heart disease in Singapore: Results from the Dyslipidemia International Study II

10.11622/smedj.2019021 · 2019 · External reference

Low-density lipoprotein cholesterol target attainment in patients with stable or acute coronary heart disease in the Asia-Pacific region: Results from the Dyslipidemia International Study II

10.1177/2047487318798927 · 2018 · External reference

Use of guideline-recommended management in established coronary heart disease in the observational DYSIS II study

10.1016/j.ijcard.2018.06.008 · 2018 · External reference

Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US

10.1001/jamacardio.2021.1810 · 2021 · External reference

Ticagrelor with or without aspirin in high-risk patients after PCI

10.1056/nejmoa1908419 · 2019 · External reference

Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: The TICO randomized clinical trial

10.1001/jama.2020.7580 · 2020 · External reference

Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial

10.1001/jama.2019.8145 · 2019 · External reference

Early discontinuation of aspirin after PCI in low-risk acute myocardial infarction

10.1056/nejmoa2508808 · 2025 · External reference

Early withdrawal of aspirin after PCI in acute coronary syndromes

10.1056/nejmoa2507980 · 2025 · External reference

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)

10.1016/s0140-6736(96)09457-3 · 1996 · External reference

Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: The HOST-EXAM extended study

10.1161/circulationaha.122.062770 · 2023 · External reference

Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation

10.1056/nejmoa1817083 · 2019 · External reference

Antithrombotic therapy for atrial fibrillation with stable coronary disease

10.1056/nejmoa1904143 · 2019 · External reference

Aspirin in patients with chronic coronary syndrome receiving oral anticoagulation

10.1056/nejmoa2507532 · 2025 · External reference

Reactive oxygen species scavenging nanomedicine for the treatment of ischemic heart disease

10.1002/adma.202202169 · 2022 · External reference

Efficacy and safety of low-dose colchicine after myocardial infarction

10.1056/nejmoa1912388 · 2019 · External reference

Colchicine in patients with chronic coronary disease

10.1056/nejmoa2021372 · 2020 · External reference

Colchicine in acute myocardial infarction

10.1056/nejmoa2405922 · 2025 · External reference

Empagliflozin after acute myocardial infarction

10.1056/nejmoa2314051 · 2024 · External reference

Dapagliflozin in myocardial infarction without diabetes or heart failure

10.1056/evidoa2300286 · 2024 · External reference

Secondary analysis of the EMPACT-MI trial reveals cardiovascular–kidney efficacy and safety of empagliflozin after acute myocardial infarction

10.1038/s44161-025-00657-7 · 2025 · External reference

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials

10.1016/s2213-8587(21)00203-5 · 2021 · External reference

Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): A multicentre, open-label, randomised controlled trial

10.1016/s0140-6736(24)00413-6 · 2024 · External reference

Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial

10.1093/eurheartj/ehab509 · 2022 · External reference

Impact of complete revascularization in the ISCHEMIA trial

10.1016/j.jacc.2023.06.015 · 2023 · External reference

Percutaneous coronary intervention in stable angina (ORBITA): A double-blind, randomised controlled trial

10.1016/s0140-6736(17)32714-9 · 2018 · External reference

A placebo-controlled trial of percutaneous coronary intervention for stable angina

10.1056/nejmoa2310610 · 2023 · External reference

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

10.1056/nejmoa041031 · 2004 · External reference

Uremia-associated immune defect: The IL-10–CRP axis

10.1046/j.1523-1755.63.s84.14.x · 2003 · External reference

Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)

10.1038/ki.2011.223 · 2011 · External reference

Management of coronary disease in patients with advanced kidney disease

10.1056/nejmoa1915925 · 2020 · External reference

Predictors of outcome in the ISCHEMIA-CKD trial: Anatomy versus ischemia

10.1016/j.ahj.2021.09.008 · 2022 · External reference

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

10.1161/cir.0000000000001168 · 2023 · External reference